Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable ...

COPENHAGEN, Denmark I June 26, 2025 I Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support ...

Clinical trials of Jynneos have begun or will begin soon in infants and children 2 years old and younger, and in pregnant or ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

Ireland has reported the first case anywhere of mpox in a fully vaccinated person, despite having a high immune response at ...

Looking ahead to the rest of the year, Bavarian Nordic aims to grow earnings some 26% to 30% over that same span. As for what could be next in the company’s travel health portfolio, Bavarian ...

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding ...

Tech transfer of MVA-BN® will help increase global mpox vaccine manufacturing capacity and further expand the equitable access to vulnerable populations.Serum Institute of India obtains license to MVA ...

Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population aged two to 11 years old. This marks the first study of the single-dose, ...

Bavarian Nordic is running a Phase II trial (NCT06549530) to evaluate the immunogenicity and safety of the Jynneos vaccine in children from two years to less than 12 years of age compared to adults ...